Marker Therapeutics, Inc.
Marker Therapeutics, Inc. (Nasdaq Capital Market: MRKR) is a clinical-stage immuno-oncology company specializing in the development of novel T cell-based immunotherapies for treating hematological malignancies and solid tumors. The company's website is located at www.markertherapeutics.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Marker Therapeutics, Inc. does
In the company’s own words
Marker Therapeutics, Inc. (Nasdaq Capital Market: MRKR) is a clinical-stage immuno-oncology company specializing in the development of novel T cell-based immunotherapies for treating hematological malignancies and solid tumors. The company's website is located at www.markertherapeutics.com.
The company's core technology platform centers on Multi Antigen Recognizing (MAR)-T cell therapy, which selectively expands natural tumor-specific T cells from patient or donor blood capable of recognizing multiple tumor-associated antigens without genetic modification. Unlike engineered CAR-T therapies that target single antigens, MAR-T cells are designed to recognize hundreds of different epitopes within up to six tumor-specific antigens simultaneously, thereby reducing the risk of tumor escape through antigen downregulation or negative selection.
Marker's clinical pipeline includes two primary product candidates. MT-601 is an autologous MAR-T cell product targeting six antigens (Survivin, PRAME, WT1, NY-ESO-1, SSX-2, and MAGEA-4) currently in Phase 1 development for relapsed lymphoma patients who have failed or are ineligible for anti-CD19 CAR-T therapy, as well as in Phase 1 for pancreatic cancer in combination with frontline chemotherapy. MT-401-OTS is an off-the-shelf product targeting four antigens currently in Phase 1 development for acute myeloid leukemia and myelodysplastic syndrome, with potential expansion to other indications.
The company licensed its foundational MAR-T technology from Baylor College of Medicine in March 2018, which had previously treated over 150 patients across seven exploratory clinical trials. Marker has optimized the manufacturing process, reducing production time from 36 days to nine days while improving potency fourfold. The company manufactures products through collaborations with contract development and manufacturing organizations, including Baylor College of Medicine and Cellipont Bioservices.
Marker's competitive advantages include the non-engineered nature of its T cell products, which reduces manufacturing complexity and cost compared to genetically modified therapies, combined with a favorable safety profile demonstrating no treatment-related neurotoxicity or severe adverse effects attributed to MAR-T cells in clinical trials to date. The company received orphan drug designation for MT-601 in pancreatic cancer and has secured grant funding from the Cancer Prevention and Research Institute of Texas and the National Institutes of Health to support clinical development.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- HOUSTON, TX
- Fiscal year end
- December
- CIK
- 1094038
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Marker Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Marker Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Marker Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Marker Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Marker Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”